Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects with Severe, Refractory Systemic Lupus Erythematosus

Recruiting

Phase 1

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects with Severe, Refractory Systemic Lupus Erythematosus

Sponsor:

Synthekine

Code:

NCT06544330

Conditions

Systemic Lupus Erythematosus

Lupus Nephritis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SYNCAR-001

STK-009

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information